MedX Health seeks final 30-day extension for convertible note placement
MedX Health Corp. (TSX-V: MDX) has applied to the TSX Venture Exchange for a final 30-day extension to May 15, 2026, to complete additional closings of its non-brokered private placement of Series IV Convertible Loan Notes.
The company completed an initial closing on February 27, 2026, raising $2.7 million through the issuance of Series IV Notes. The extension would allow MedX to raise up to an additional $2.3 million through further closings.
The Series IV Notes carry a 6% annual interest rate paid quarterly and mature on December 31, 2028. Note holders may convert their securities into units at $0.10 per unit until maturity. Each unit consists of one common share and half of a share purchase warrant, with each full warrant exercisable at $0.125 until the maturity date.
Holders of Series I Convertible Loan Notes, which matured on December 31, 2025, may exchange their notes for Series IV Notes. The Series I Notes had a conversion price of $0.14 and warrant exercise price of $0.20.
Qualified agents will receive a 6% cash commission on gross proceeds from subscribers they introduce, plus agent's warrants equal to 6% of those subscriptions. The agent's warrants are exercisable at CAD$0.10 for units comprising one common share and half of a share purchase warrant exercisable at CAD$0.125.
The company stated that certain insiders may participate in the placement, subject to regulatory exemptions. Proceeds will fund redemption of unconverted Series I Notes, development of the company's SIAscopy technology and DermSecure telemedicine platform, expansion into occupational health markets, and general corporate purposes.
MedX Health operates a medical technology platform focused on non-invasive skin screening and teledermatology through proprietary imaging technology cleared for use in multiple jurisdictions including Canada, the United States, and the European Union.
You May Also Be Interested In
- RedHill Biopharma closes $6M private placement with warrant upside
- Upexi prices $19.5M private placement to reduce existing debt
- ZenaTech raises Plurilock Security stake to 12% with new share purchase
Create E-mail Alert Related Categories
Equity OfferingsRelated Entities
Definitive Agreement, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share